-
Product Insights
NewGrowth Hormone Deficiency – Drugs In Development, 2024
Empower your strategies with our Growth Hormone Deficiency – Drugs In Development, 2024 report and make more profitable business decisions. Growth hormone deficiency (GHD) is a rare and treatable condition that occurs when the pituitary gland does not produce enough growth hormone (GH). GH is a hormone that stimulates growth and metabolism in the body. GHD can affect children and adults, but it has different effects depending on the age of onset. Children with GHD have short stature, delayed puberty, low...
-
Product Insights
NewHemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hemophilia A is an X-linked recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury, or in the case of severe hemophilia, spontaneous hemorrhage. Symptoms may include bleeding...
-
Product Insights
NewMycobacterium tuberculosis Infections – Drugs In Development, 2024
Empower your strategies with our Mycobacterium tuberculosis Infections – Drugs In Development, 2024 report and make more profitable business decisions. The group of infections caused by Mycobacterium tuberculosis (M. tuberculosis) are referred to as Mycobacterium tuberculosis infections, which primarily affect the lungs but can also impact other parts of the body. The symptoms include persistent cough, fever, weight loss, and night sweats. Treatment typically involves a combination of antibiotics taken over several months. M. tuberculosis infections remain a significant global health...
-
Product Insights
NewTuberculosis – Drugs In Development, 2024
Empower your strategies with our Tuberculosis – Drugs In Development, 2024 report and make more profitable business decisions. Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus; fatigue; shortness of breath; weight...
-
Product Insights
Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include an overall sensation of feeling unwell, cough, possibly bloody mucus, fatigue, shortness of breath, weight loss, and pain in the chest. The Tuberculosis pipeline market research report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive...
-
Product Insights
Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Human Immunodeficiency Virus Pipeline market research report provides a comprehensive overview on the therapeutics under development for Human Immunodeficiency Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...